Waldenström Macroglobulinemia

Blood Cancers

Brain Cancer

Metastatic Breast Cancer

Breast Cancer

Childhood Cancers

Anal Cancer

Colorectal Cancer

Esophageal Cancer

Gallbladder Cancer

Gastrointestinal stromal tumor

Liver Cancer

Pancreatic Cancer

Gastrointestinal Cancers

Bladder Cancer

Kidney Cancer

Prostate Cancer

Testicular Cancer

Genitourinary Cancers

Cervical Cancer

Ovarian Cancer

Uterine Cancer

Vulvar Cancer

Gynecologic Cancer

Head & Neck Cancer

Immunotherapy

Acute Myeloid Leukemia

Leukemia

Mesothelioma

Lung Cancer

Follicular Lymphoma

Mantle Cell Lymphoma

Non-Hodgkin Lymphoma

Small Lymphocytic Lymphoma (SLL)

Lymphoma

Myeloma

Cancer of Unknown Primary

Carcinoid Cancer

Neuroendocrine Cancer

Rare Cancers

Sarcoma

Melanoma

Skin Cancer

Thyroid Cancer

News

Cancer Horizons

All News

Blogs

Caregiving

Diet and Exercise

Financial

Psychosocial

Recipes

Sexual Health

Side Effect

Survivorship

Videos

All Videos

CURE Connections

CURE Expert Connections®

CURE Speaking Out

CURE TV

Educated Patient Sound Bites

On Demand: Webinars

Conferences

Conference Coverage 

Conference Listing 

Events

CURE Adventures

CURE Awards

Educated Patient In Person Education

Educated Patient Virtual Education

Resources

Advocacy Groups

Art Gallery

Clinical Trial Corner

Heal®

Partners

Podcasts

Publications

Share Your Story

Subscribe

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of the cancer experience.

About Us

Advertise / Support

Contact Us

CancerNetwork.com

TargetedOnc.com

OncLive.com

OncNursingNews.com

Terms & Conditions

Privacy

Do Not Sell My Information

CURE - Oncology & Cancer News for Patients & Caregivers

Facebook

Youtube

Instagram

Spotlight

Breast Cancer Webinar Series

Cancer Type

Bladder

Breast

Kidney

Lung

Ovarian

Prostate

Skin

About CURE

Press Releases

Write for CURE

1rem

View

Advances in Myelofibrosis Treatment and Enhancing Patient Quality of Life

Management of Anemia in Patients With Myelofibrosis

Christine Cooper, RN, BSN, and Aaron Gerds, MD, MS,discuss optimizing outcomes and quality-of-life in patients with myelofibrosis, the current treatment options and promising advances, and side-effect management.

Patients with myelofibrosis commonly present with fatigue, weight loss, night sweats, bone pain, low blood counts, and concentration issues, with diagnosis requiring bone marrow biopsy.

Diagnosing Myelofibrosis

To determine risk level in myelofibrosis, prognostic models are used which assign points to various clinical and pathological factors to calculate a risk score that categorizes patients as low, intermediate, or high risk; additional information like mutations and chromosomes can further refine risk stratification.

Assessing Risk Level of Patients With Myelofibrosis

Patients should be directed to resources like the NCCN guidelines and ClinicalTrials.gov and provided with thorough discussions covering frequency of visits, required testing, medication administration, side effects to enable fully informed decisions.

Educational Resources for Patients Diagnosed With Myelofibrosis

Key patient goals for managing myelofibrosis include improving quality of life by addressing low blood counts and constitutional symptoms, considering disease-modifying therapies and transplant to maximize longevity based on predicted survival, and incorporating personalized priorities through shared decision-making with their doctor when choosing treatments.

Key Patient Goals for Myelofibrosis Management

Christine Cooper, RN, BSN, explains anemia in myelofibrosis is managed by stimulating red blood cell production with medications, transfusions, and newer therapies that may stabilize red cell counts.

An expert discusses the four FDA-approved JAK inhibitors for myelofibrosis - ruxolitinib, fedratinib, pacritinib, and momelotinib.

Clinical Data on the Approved JAK Inhibitors for Treatment of Myelofibrosis

The JAK inhibitors approved for myelofibrosis have common side effects of cytopenias and gastrointestinal issues, with additional risks of weight gain and cardiac effects and diarrhea; momelotinib and pacritinib show improved tolerability compared to earlier JAK inhibitors.

Adverse Events Seen With JAK Inhibitors for Myelofibrosis

Response is assessed in patients starting a JAK inhibitor by monitoring symptoms on a severity scale, spleen size, blood counts, and overall patient impression of change, with the goal being reduction of symptoms and stabilization of blood counts to improve quality of life.

Assessing Treatment Response in Patients With Myelofibrosis

Reasons to switch JAK inhibitors include worsening blood counts and insufficient symptom or spleen response at maximum doses, with the goal of avoiding gaps in treatment by stopping one JAK inhibitor when ready to start the next to prevent symptom rebound while still allowing for potential increased efficacy from an alternative mechanism of action.

Best Approaches to Switching Therapies for a Patient With Myelofibrosis

For most JAK inhibitors dosing starts at the maximum safe dose, while ruxolitinib often requires lower initial doses and dose reductions over the first 12 weeks when cytopenias typically worsen before partially improving, warranting consideration of earlier switching to alternative JAK inhibitors instead of pushing through transfusions.

Dosing JAK Inhibitors in Patients With Myelofibrosis

Patients with myelofibrosis should reflect on their personal priorities and quality of life goals, understand the range of available JAK inhibitor treatment options, and openly communicate with their doctor to arrive at a shared decision for managing their disease.

Key Takeaways for Patients With Myelofibrosis

CURE Expert Connections® is a video series designed to help patients and their loved ones along their cancer care journey by offering information and expert advice from leaders in oncology care. Expert medical professionals share their knowledge and insights on an array of topics to allow for a better understanding of what to expect following a cancer diagnosis. Expert Connections hopes to bridge the gap between patients and oncology professionals to ensure no question is left unanswered.

Management of Anemia in Patients With Myelofibrosis

EP: 1.Diagnosing Myelofibrosis

EP: 2.Assessing Risk Level of Patients With Myelofibrosis

EP: 3.Educational Resources for Patients Diagnosed With Myelofibrosis

EP: 4.Key Patient Goals for Myelofibrosis Management

EP: 5.Management of Anemia in Patients With Myelofibrosis

EP: 6.Clinical Data on the Approved JAK Inhibitors for Treatment of Myelofibrosis

EP: 7.Adverse Events Seen With JAK Inhibitors for Myelofibrosis

EP: 8.Assessing Treatment Response in Patients With Myelofibrosis

EP: 9.Best Approaches to Switching Therapies for a Patient With Myelofibrosis

EP: 10.Dosing JAK Inhibitors in Patients With Myelofibrosis

EP: 11.Key Takeaways for Patients With Myelofibrosis

Newsletter